Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research discusses the potential antitumor effects of metformin, a common diabetes medication, noting its controversial influence on different malignant tumors and its uncertain mechanisms. Understanding these effects on tumors may aid in the development of new cancer treatments.

This paper reports that while metformin may improve fertility outcomes and reduce miscarriage rates in women with PCOS, its efficacy can differ depending on the specific treatment combination used.

This study found that genetic polymorphisms of OCT1 influence the effectiveness of metformin treatment in improving insulin sensitivity among PCOS patients, suggesting a role for personalized treatment strategies.

This article reviews recent data suggesting that metformin may be beneficial for anovulatory PCOS patients with normal BMI and clomiphene resistance but emphasizes that more studies are needed to confirm these findings.

This randomized clinical trial found that vitamin D supplementation did not significantly alter anthropometric or metabolic parameters in obese, insulin-resistant, and vitamin D-deficient women with polycystic ovary syndrome, whereas metformin effectively reduced body weight, BMI, waist circumference, total body fat, and serum glucose levels.

This review found that metformin was an effective adjunct therapy for treating moderate-to-severe acne vulgaris in patients without polycystic ovary syndrome or androgen excess.

In this study, spironolactone and spironolactone plus metformin both significantly reduced hirsutism scores in women with PCOS, but the combination therapy was not more effective than spironolactone alone regarding BMI, hormone levels, or insulin resistance.

This study found that type 2 diabetes mellitus does not affect the pharmacokinetics of metformin in obese pregnant women with PCOS, suggesting no need for dosage adjustments.

This study aimed to identify reliable predictors for the effectiveness of metformin therapy in weight loss and reduction of plasma androgen levels in PCOS women, highlighting the unpredictability of response to treatment.

This case study describes a 19-year-old female with hidradenitis suppurativa whose symptoms and metabolic abnormalities improved significantly over 3 years on a combined regimen, though some skin lesions persisted.

This study found that combining low-dose spironolactone with metformin improved insulin resistance in PCOS patients more effectively than using either drug alone.

This study observed that adding simvastatin to ongoing metformin treatment reduced certain androgen levels in women with non-classic congenital adrenal hyperplasia and abnormal glucose metabolism, suggesting a potential therapeutic benefit.

This review summarizes recent studies on metformin for polycystic ovary syndrome, reporting its beneficial effects on endocrine, metabolic, and reproductive outcomes, but highlights ongoing debate about its mechanisms.

In this study, metformin improved BMI, menstrual regularity, and symptoms of hyperandrogenism in adolescents with type 1 diabetes, but did not enhance glycemic control.

This study found that metformin treatment improved clinical outcomes in Taiwanese women with polycystic ovary syndrome, notably in overweight and insulin-resistant patients.

This narrative review reports that metformin, traditionally used for type 2 diabetes management, may offer therapeutic benefits for various skin disorders, such as acne, rosacea, and psoriasis, due to its anti-inflammatory and other beneficial properties, warranting further exploration in dermatology.

In this study, metformin promoted hair follicle regeneration in vitro by enhancing the hair inductive capability of dermal cells, warranting further exploration for pattern hair loss treatment.

This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.

Metformin can cause hair loss in some women with PCOS.

This study concluded that fenugreek improved lipid profiles in women with PCOS compared to metformin, but cannot substitute metformin for PCOS treatment; it may serve as an adjuvant therapy for those with hyperlipidemia.

This study found that topical metformin was as effective as triple combination cream in reducing melasma severity, with minimal adverse events.

This study found that metformin's metabolic benefits, such as reducing fat content and improving insulin sensitivity, were less pronounced in men with early-onset androgenic alopecia compared to those with normal hair growth, possibly due to differences in systemic inflammation and vitamin D status.

This study found that both finasteride and metformin effectively reduced androgen levels and insulin resistance parameters in women with PCOS, without clear evidence of one treatment being superior.

Metformin and thiazolidinediones are similarly effective for PCOS, but metformin is often preferred due to fewer side effects.

This review examines the antitumor effects of metformin and highlights discrepancies between basic and clinical study results, noting that these may be due to different dosing levels.

This study found that three months of metformin therapy improved acne, hirsutism, and menstrual irregularities in women with PCOS, along with hormonal and ultrasonographic changes.

This study found that in overweight or obese women with PCOS and insulin resistance, those with lower baseline prolactin levels exhibited a greater decrease in insulin resistance after 6-8 months of metformin treatment, compared to those with higher prolactin levels.

This review discusses polycystic ovarian syndrome, particularly in Saudi Arabia, and metformin's use and mechanism in treating related infertility, without presenting new clinical findings.

This study found that topical application of metformin significantly enhanced skin regeneration in mechanically stretched skin in rats, likely by boosting the proliferation of skin-derived stem cells.

This report presents a case of a female with PCOS treated with metformin who developed hyperuricemia, severe joint and neurological pain, and later experienced a hypersensitivity reaction to benzathine benzyl penicillin.